Multimodal plasma metabolomics and lipidomics in elucidating metabolic perturbations in tuberculosis patients with concurrent type 2 diabetes.

English summary

This study applied a multimodal plasma metabolomics and lipidomics workflow to characterize metabolic perturbations in patients with tuberculosis (TB) and concurrent type 2 diabetes mellitus (DM). Compared with TB alone, TB-DM was associated with differences in carbohydrate, amino acid, and lipid metabolism, including potentially important changes in arachidonic acid metabolism.

Key points

• A data-driven, knowledge-based framework was used to identify significantly different biological processes and biomarkers between the TB-DM and TB groups.
• Amide HILIC-column metabolomics primarily captured changes in pathways related to carbohydrate and amino acid metabolism, whereas C18 metabolomics and lipidomics identified perturbations in lipid metabolism.
• Relative to TB, TB-DM showed higher levels of bile acids and molecules related to carbohydrate metabolism, together with depletion of glutamine, retinol, lysophosphatidylcholine, and phosphatidylcholine, as reported in the source text.

Audience

Clinicians, researchers, and advanced students interested in TB–diabetes comorbidity, metabolomics- and lipidomics-based biomarkers, and precision-medicine approaches to disease pathophysiology.

Scope and limitations

This summary is based only on the supplied primary-source text. The source does not provide detailed information on participant characteristics, sample size, independent validation, follow-up, statistical effect sizes, or causal inference; therefore, the reported metabolic changes cannot be interpreted from this text alone as causes of TB-DM or as evidence that treatment outcomes would improve.

Research context

The study is thematically connected to the integration of metabolomic and lipidomic data for biomarker discovery in comorbid disease, a topic relevant to molecular profiling of pathophysiology in pharmacology and precision medicine.